iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 12.2% in November

iBio, Inc. (NYSEAMERICAN:IBIO) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 202,800 shares, a drop of 12.2% from the November 15th total of 230,900 shares. Approximately 2.2% of the company’s stock are sold short. Based on an average daily trading volume, of 135,900 shares, the short-interest ratio is currently 1.5 days.

iBio Stock Down 8.0 %

iBio stock traded down $0.20 during mid-day trading on Friday, reaching $2.31. 132,576 shares of the company were exchanged, compared to its average volume of 1,093,175. iBio has a twelve month low of $1.02 and a twelve month high of $4.98. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.